Germany · Delayed Price · Currency is EUR Biotage AB Company Description
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing.
The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal and supported scavengers and reagents, as well as accessories and spare parts.
It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables, systems, and workflows; biomolecule purification solutions, including antibody, plasmid, AAV, and tagged proteins purification; automation systems; and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns.
The company serves pharmaceutical and biotechnical companies, police and criminal investigators contract research and manufacturing organizations, academic laboratories, hospitals, and sports events, as well as diagnostics, clinical, environmental protection, food safety, clinical, and forensic industries.
It operates in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.
| Country | Sweden |
| Founded | 1969 |
| Industry | Laboratory Analytical Instruments |
| Employees | 680 |
| CEO | Frederic Vanderhaegen |
Contact Details
Address: Vimpelgatan 5 Uppsala, 751 03 Sweden | |
| Phone | 46 18 56 59 00 |
| Website | biotage.com |
Stock Details
| Ticker Symbol | PQX1 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Frederic Vanderhaegen | Chief Executive Officer |
| Andrew Kellett | Chief Financial Officer |
| Scott Carr | Chief Operating Officer |